CY2526B1 - Compositions and methods for reducing ocular hypertension - Google Patents

Compositions and methods for reducing ocular hypertension

Info

Publication number
CY2526B1
CY2526B1 CY0500033A CY0500033A CY2526B1 CY 2526 B1 CY2526 B1 CY 2526B1 CY 0500033 A CY0500033 A CY 0500033A CY 0500033 A CY0500033 A CY 0500033A CY 2526 B1 CY2526 B1 CY 2526B1
Authority
CY
Cyprus
Prior art keywords
compositions
methods
ocular hypertension
reducing ocular
reducing
Prior art date
Application number
CY0500033A
Other languages
English (en)
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2526(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2526B1 publication Critical patent/CY2526B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY0500033A 1997-03-17 2005-05-26 Compositions and methods for reducing ocular hypertension CY2526B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
CY2526B1 true CY2526B1 (en) 2006-02-08

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0500033A CY2526B1 (en) 1997-03-17 2005-05-26 Compositions and methods for reducing ocular hypertension

Country Status (33)

Country Link
EP (1) EP0969846B2 (da)
JP (2) JP4920124B2 (da)
KR (1) KR100555818B1 (da)
CN (1) CN1236775C (da)
AR (2) AR002194A1 (da)
AT (1) ATE257385T1 (da)
AU (1) AU738781B2 (da)
BR (2) BR9808016A (da)
CA (1) CA2280089C (da)
CL (1) CL2009001870A1 (da)
CO (1) CO4940427A1 (da)
CY (1) CY2526B1 (da)
CZ (1) CZ299833B6 (da)
DE (1) DE69820997T3 (da)
DK (1) DK0969846T4 (da)
EE (1) EE04091B1 (da)
ES (1) ES2214706T5 (da)
HK (1) HK1026841A1 (da)
HU (1) HU228896B1 (da)
ID (1) ID22389A (da)
IL (1) IL131041A0 (da)
MY (1) MY122237A (da)
NO (1) NO327713B1 (da)
NZ (1) NZ337322A (da)
PE (1) PE61899A1 (da)
PL (1) PL197509B1 (da)
PT (1) PT969846E (da)
RU (1) RU2197970C2 (da)
SI (1) SI0969846T2 (da)
TW (1) TW527187B (da)
UA (1) UA63938C2 (da)
WO (1) WO1998041208A1 (da)
ZA (1) ZA982188B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
US20040097592A1 (en) * 2000-09-13 2004-05-20 Kenji Morishima Eye drops
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
US20070208068A1 (en) * 2004-03-18 2007-09-06 R-Tech Ueno, Ltd. & Astellas Pharma Inc. Aqueous Composition Comprising Thiazole Derivative
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
CN101400354B (zh) * 2006-03-13 2014-10-22 株式会社·R-技术上野 水性组合物
US8466174B2 (en) * 2006-03-17 2013-06-18 Johnson & Johnson Vision Care, Inc. Methods for stabilizing oxidatively unstable compositions
US20080107644A1 (en) * 2006-10-31 2008-05-08 Alcon Manufacturing, Ltd. Pai-1 binding modulators for the treatment of ocular disorders
JPWO2008096804A1 (ja) * 2007-02-07 2010-05-27 テイカ製薬株式会社 ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
WO2009046967A1 (en) * 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
EP2420223B1 (en) * 2008-03-17 2017-07-19 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
IN2014CN04809A (da) 2011-12-07 2015-09-18 Allergan Inc
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
EP3223794A1 (en) 2014-11-25 2017-10-04 Allergan, Inc. Stabilized omega-3 ophthalmic compositions
CA3113528A1 (en) * 2018-09-21 2020-03-26 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
US11312922B2 (en) 2019-04-12 2022-04-26 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner comprising a sulfonic acid-containing surfactant and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE91419T1 (de) * 1990-05-22 1993-07-15 R Tech Ueno Ltd Synergistische kombination zur ophthalmischen verwendung.
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
AU738781B2 (en) 2001-09-27
CO4940427A1 (es) 2000-07-24
ES2214706T3 (es) 2004-09-16
BR9808016A (pt) 2000-03-08
ZA982188B (en) 1998-09-17
JP2001515502A (ja) 2001-09-18
HU228896B1 (en) 2013-06-28
DE69820997T2 (de) 2004-12-09
ID22389A (id) 1999-10-07
JP2010043110A (ja) 2010-02-25
TW527187B (en) 2003-04-11
NO327713B1 (no) 2009-09-14
EE9900410A (et) 2000-04-17
HK1026841A1 (en) 2000-12-29
NZ337322A (en) 2001-05-25
EP0969846B2 (en) 2010-08-25
JP4920124B2 (ja) 2012-04-18
ATE257385T1 (de) 2004-01-15
DE69820997T3 (de) 2011-10-06
BRPI9816218B1 (pt) 2016-04-12
AU7035398A (en) 1998-10-12
KR100555818B1 (ko) 2006-03-03
RU2197970C2 (ru) 2003-02-10
PL197509B1 (pl) 2008-04-30
DE69820997D1 (de) 2004-02-12
DK0969846T3 (da) 2004-04-13
SI0969846T2 (sl) 2010-12-31
CL2009001870A1 (es) 2010-01-22
AR002194A1 (es) 1998-01-07
PL335168A1 (en) 2000-04-10
EP0969846A1 (en) 2000-01-12
CA2280089A1 (en) 1998-09-24
PT969846E (pt) 2004-05-31
IL131041A0 (en) 2001-01-28
WO1998041208A1 (en) 1998-09-24
DK0969846T4 (da) 2010-12-20
ES2214706T5 (es) 2011-02-02
CN1236775C (zh) 2006-01-18
EP0969846B1 (en) 2004-01-07
NO994481D0 (no) 1999-09-16
UA63938C2 (uk) 2004-02-16
CZ325799A3 (cs) 2000-01-12
NO994481L (no) 1999-09-16
SI0969846T1 (en) 2004-06-30
CA2280089C (en) 2009-03-03
MY122237A (en) 2006-04-29
AR011192A1 (es) 2000-08-02
EE04091B1 (et) 2003-08-15
HUP0002194A3 (en) 2012-08-28
CZ299833B6 (cs) 2008-12-10
PE61899A1 (es) 1999-06-30
CN1249687A (zh) 2000-04-05
KR20000076330A (ko) 2000-12-26
HUP0002194A2 (hu) 2000-12-28

Similar Documents

Publication Publication Date Title
CY2526B1 (en) Compositions and methods for reducing ocular hypertension
ZA958028B (en) Compositions and methods for treatig mast-cell mediated conditions
AU9214398A (en) Compositions and methods for treating water
AU8693098A (en) Compositions and methods for treating diabetes
IL133784A0 (en) Dolastatin 15 derivatives
ZA989399B (en) Method and composition
AU2349399A (en) R-lansoprazole compositions and methods
ZA989398B (en) Method and composition (l)
EP1056457A4 (en) S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE
GB9624501D0 (en) Insecticial compositions and method
EP1073333A4 (en) S-RABEPRAZOL COMPOSITIONS AND METHODS
AU5342498A (en) Difluprednate-containing ophthalmic o/w emulsion composition
AUPO982097A0 (en) Methods and compositions for use therein
AU5546298A (en) Methods and compositions for preventing autoimmune disease
EP1073332A4 (en) R-RABEPRAZOL COMPOSITIONS AND METHODS
AU3900499A (en) (+)-hydroxyrisperidone compositions and methods
AU7287798A (en) Compositions and methods for bioremediation
AU7799898A (en) Compositions and methods for treating glaucoma
AU9105498A (en) Novel compositions and methods for controlling nematodes
AU9474898A (en) Methods and compositions for diagnosing and treating malaria
GB9719842D0 (en) Ophthalmic compositions for treating ocular hypertension
GB9717153D0 (en) Eyedrop composition
GB9723679D0 (en) Method and composition
GB9720422D0 (en) Composition and method
GB9720017D0 (en) Composition and method